Literature DB >> 12653840

Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16).

B M Kumpel1, M De Haas, H R Koene, J G J Van De Winkel, M J Goodrick.   

Abstract

Human red cells (RBC) coated with IgG anti-D are cleared from the circulation to the spleen by macrophages which express IgG receptors (Fcgamma R). Polymorphisms of Fcgamma RIIa and Fcgamma RIIIa affect IgG binding in vitro, and may alter the efficiency of clearance of immune complexes in vivo. In a RBC clearance study, 22 Rh D-negative subjects were given 100-400 micro g human monoclonal or polyclonal IgG anti-D i.m. followed 48 h later by 51Cr-labelled D+ RBC. The half lives of the infused D+ RBC were determined, together with the coating levels of anti-D on the D+ RBC. Fcgamma RIIA and FcgammaRIIIA genotyping was performed. Large ranges of phagocytosis and extracellular lysis of RBC in vitro, and of half lives of RBC in vivo, were observed. Clearance of RBC coated with monoclonal IgG3 anti-D (BRAD-3) was more rapid in five subjects homozygous for Fcgamma RIIIa-F/F158 than in three subjects expressing the Fcgamma RIIIa-V158 allele (P = 0.024). This effect was not observed, however, for those individuals given polyclonal anti-D. There was also no significant difference in the efficiency of RBC destruction in vitro or of RBC clearance in vivo between the subjects analysed for individual genotypes or alleles or combinations of alleles. In conclusion, the presence of the Fcgamma RIIIa-V158 allele compromised the efficiency of removal of RBC coated with IgG3 anti-D.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653840      PMCID: PMC1808672          DOI: 10.1046/j.1365-2249.2003.02119.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

1.  A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.

Authors:  J Wu; J C Edberg; P B Redecha; V Bansal; P M Guyre; K Coleman; J E Salmon; R P Kimberly
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  RATE OF REMOVAL FROM THE CIRCULATION OF RED CELLS SENSITIZED WITH DIFFERENT AMOUNTS OF ANTIBODY.

Authors:  P L MOLLISON; P CROME; N C HUGHES-JONES; E ROCHNA
Journal:  Br J Haematol       Date:  1965-07       Impact factor: 6.998

3.  A pharmacokinetic/pharmacodynamic model for the action of anti-D immunoglobulin in effecting circulatory clearance of Rh D+ red cells.

Authors:  G E Chapman
Journal:  Transfus Med       Date:  1996-09       Impact factor: 2.019

4.  In vitro functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D.

Authors:  B M Kumpel
Journal:  Vox Sang       Date:  1997       Impact factor: 2.144

5.  Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding.

Authors:  J C Edberg; R P Kimberly
Journal:  J Immunol       Date:  1997-10-15       Impact factor: 5.422

6.  Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes.

Authors:  H M Dijstelbloem; M Bijl; R Fijnheer; R H Scheepers; W W Oost; M D Jansen; W J Sluiter; P C Limburg; R H Derksen; J G van de Winkel; C G Kallenberg
Journal:  Arthritis Rheum       Date:  2000-12

7.  Fc gamma RIIa polymorphism in systemic lupus erythematosus.

Authors:  L J Smyth; N Snowden; D Carthy; C Papasteriades; A Hajeer; W E Ollier
Journal:  Ann Rheum Dis       Date:  1997-12       Impact factor: 19.103

8.  Fc gamma receptor-dependent clearance is enhanced following lipopolysaccharide in vivo treatment.

Authors:  M S Palermo; F Alves Rosa; G Fernández Alonso; M A Isturiz
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

9.  Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

Authors:  H R Koene; M Kleijer; J Algra; D Roos; A E von dem Borne; M de Haas
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

10.  Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; S E McKenzie; X M Jiang; M Poncz; D B Cines
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

View more
  5 in total

1.  Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass.

Authors:  M Holland; P Hewins; M Goodall; D Adu; R Jefferis; C O S Savage
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

2.  Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn.

Authors:  Rick Kapur; Luciana Della Valle; Myrthe Sonneveld; Agnes Hipgrave Ederveen; Remco Visser; Peter Ligthart; Masja de Haas; Manfred Wuhrer; C Ellen van der Schoot; Gestur Vidarsson
Journal:  Br J Haematol       Date:  2014-06-07       Impact factor: 6.998

3.  Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.

Authors:  Gillian Dekkers; Louise Treffers; Rosina Plomp; Arthur E H Bentlage; Marcella de Boer; Carolien A M Koeleman; Suzanne N Lissenberg-Thunnissen; Remco Visser; Mieke Brouwer; Juk Yee Mok; Hanke Matlung; Timo K van den Berg; Wim J E van Esch; Taco W Kuijpers; Diana Wouters; Theo Rispens; Manfred Wuhrer; Gestur Vidarsson
Journal:  Front Immunol       Date:  2017-08-02       Impact factor: 7.561

4.  Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice.

Authors:  Rens Braster; Simran Grewal; Remco Visser; Helga K Einarsdottir; Marjolein van Egmond; Gestur Vidarsson; Marijn Bögels
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240

5.  Predicting anti-RhD titers in donors: Boostering response and decline rates are personal.

Authors:  Anneke S de Vos; C Ellen van der Schoot; Dimitris Rizopoulos; Mart P Janssen
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.